# Manel Juan

Source: https://onco.cc/people/manel-juan/  
OnCo record `manel-juan` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The Barcelona immunologist whose team designed ARI-0001 from the hospital's own antibody and made it in-house, so a public hospital could give CAR-T at lower cost.

## Summary

Manel Juan is an immunologist in the Department of Immunology at Hospital Clínic de Barcelona and FRCB-IDIBAPS, according to the affiliation on his 2026 HemaSphere paper. The AEMPS's announcement of its February 2021 authorisation of ARI-0001 says a team led by Dr Manel Juan developed the new CD19 CAR-T from the hospital's own monoclonal antibody, and quotes him on a robust, reproducible preparation method that lowers production cost so the therapy can be affordable for academic institutions. He is an author of the CART19-BE-01 and CARTBCMA-HCB-01 reports and of the 2022 Bone Marrow Transplantation article on the hospital exemption route by which ARI-0001 was authorised.

## Fields

- Kind: Person
- Last checked: 2026-11-03
- Role: Immunologist, Department of Immunology, Hospital Clínic de Barcelona and FRCB-IDIBAPS; Universitat de Barcelona
- Specialisms: Immunology; CAR-T design and manufacturing; Advanced therapies

## Sources

- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Juan%20M%5BAuthor%5D%20ARI-0001
- AEMPS: authorisation of ARI-0001 (10 February 2021): https://www.aemps.gob.es/informa/la-aemps-autoriza-el-car-t-ari-0001-del-hospital-clinic-para-pacientes-con-leucemia-linfoblastica-aguda/

## Connected records

- institutions: [Hospital Clínic de Barcelona / IDIBAPS](https://onco.cc/institutions/hospital-clinic-barcelona/)
- trials: [CART19-BE-01 (ARI-0001 CAR-T, Hospital Clínic de Barcelona)](https://onco.cc/trials/cart19-be-01/), [CARTBCMA-HCB-01 (ARI0002h BCMA CAR-T, Hospital Clínic de Barcelona)](https://onco.cc/trials/cartbcma-hcb-01/)
- key papers: [CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19(+) Relapsed/Refractory Malignancies](https://onco.cc/key-papers/paper-cart19-be-01-mol-ther-2021/), [Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study](https://onco.cc/key-papers/paper-cartbcma-hcb-01-lancet-oncol-2023/), [The hospital exemption pathway for advanced therapies and the case of the CAR-T ARI-0001](https://onco.cc/key-papers/paper-trias-hospital-exemption-ari-0001-bmt-2022/)

---
JSON: https://onco.cc/api/v1/entities/manel-juan.json